References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. 2022;72(1):7-33.
2. Zheng R, Zhang S, Zeng H, Wang S, Sun K, et al. Cancer incidence and mortality in China, 2016. J Nat Cancer Cent. 2022;2(1):1-9.
3. Guan H, Wang C, Chen C, Han S, Zhao Z. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China. Frontiers in Oncology. 2022;12:819674.
4. Shu Y, Zhang Q, He X, Chen L. Cost-effectiveness analysis of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer with EGFR mutations in China. Cancer Management and Research. 2021;13:8297.
5. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Annals of oncology. 2003;14(6):922-930.
6. Cantarini MV, McFarquhar T, Smith RP, Bailey C, Marshall AL. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. Clinical therapeutics. 2004;26(10):1630-1636.
7. Cantarini MV, Bailey CJ, Collins B, Smith RP. The relative bioavailability of gefitinib administered by granular formulation. Cancer chemotherapy and pharmacology. 2008;62(2):203-208.
8. P D, Li P, Liu H, Zhao R, Zhao Z, et al. Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions. Clin Pharmacol Drug Dev. 2019;9(5):621-628.
9. An Z, Wang X, Li P, He J, Liu L. Exploring the metabolic characteristics and pharmacokinetic variation of paroxetine in healthy volunteers using a pharmacometabonomic approach. Journal of Pharmaceutical and Biomedical Analysis. 2021:114224.
10. Culy CR, Faulds D. Gefitinib. Drugs. 2002;62(15):2237-2248.
11. Swaisland H, Laight A, Stafford L, Jones H, Morris C, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical pharmacokinetics. 2001;40(4):297-306.
12. Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews. 2015;41(5):412-422.
13. Zhang H, Li Q, Zhu X, Wu M, Li C, et al. Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy male subjects. Frontiers in pharmacology. 2018;9:849.
14. Davit BM, Kanfer I, Tsang YC, Cardot J-M. BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements. The AAPS journal. 2016;18(3):612-618.
15. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clinical pharmacokinetics. 2005;44(11):1165-1177.
16. Moon SJ, Kim Y, Jeon J-Y, Park S-J, Kwak Y-G, et al. Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects. Translational and Clinical Pharmacology. 2021;29(3):171.
17. Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. International journal of pharmaceutics. 2007;341(1-2):134-142.
18. Wan Z, Guo L, Li P, Zhao Z, Xu B, et al. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: a pharmacogenomic study of cytochrome p450 enzymes and transporters. Journal of Clinical Pharmacy and Therapeutics. 2020;45(5):1159-1167.